October 12, 2015
Lilly acquires worldwide rihgts to Locemia’s intranasal glucagon
Eli Lilly has acquired worldwide rights to Locemia’s intranasal glucagon, a potential treatment for severe hypoglycemia in people with diabetes treated with insulin.